| Insiders | Shares | % | Avg Price | Total $ | |
|---|---|---|---|---|---|
| Buys | 0 | ||||
| Sells | 7 | -2.1M | 100% | $39.98 | -$83.9M |
| Net | -7 | -2.1M | -100% | -$83.9M |
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Report Date |
|---|---|---|---|---|---|
| Invus Public Equities, L.P. | 10%+ Owner | $385M | -$82.4M | -17.6% | Dec 10, 2024 |
| Samsara BioCapital GP, LLC | 10%+ Owner | $108M | Oct 16, 2023 | ||
| Srinivas Akkaraju | Director | $102M | Oct 7, 2024 | ||
| Siren, L.L.C. | 10%+ Owner | $101M | Jul 25, 2024 | ||
| Kristina Burow | Director | $21.2M | Jun 27, 2024 | ||
| Nagesh K. Mahanthappa | Interim CEO and President | $7.65M | Jun 16, 2022 | ||
| Jay T. Backstrom | CHIEF EXECUTIVE OFFICER, Director | $5.55M | -$183K | -3.19% | Feb 16, 2024 |
| Yung H. Chyung | Chief Medical Officer | $4.12M | Feb 14, 2022 | ||
| Jing L. Marantz | Chief Medical Officer | $2.97M | -$379K | -11.3% | Nov 22, 2024 |
| David Hallal | Director | $2.73M | Jun 27, 2024 | ||
| Gregory John Carven | Chief Scientific Officer | $2.04M | Jun 16, 2022 | ||
| Junlin Ho | General Counsel | $1.83M | -$164K | -8.2% | Jun 17, 2024 |
| Edward H. Myles | Coo & Cfo | $1.61M | -$500K | -23.7% | Oct 8, 2024 |
| Michael Gilman | Director | $1.53M | Nov 12, 2024 | ||
| Caryn Parlavecchio | Chro | $1.42M | -$157K | -9.95% | Aug 16, 2024 |
| Mo Qatanani | Chief Scientific Officer | $1.22M | -$109K | -8.16% | Sep 16, 2024 |
| Amir Nashat | Director | $608K | May 9, 2024 | ||
| Tracey Sacco | Chief Commercial Officer | $493K | Oct 7, 2024 | ||
| Jeffrey S. Flier | Director | $402K | Jun 27, 2024 | ||
| Katie Peng | Director | $281K | Jun 27, 2024 | ||
| Akshay Vaishnaw | Director | $206K | Jun 27, 2024 | ||
| Richard Brudnick | Director | $121K | Jun 27, 2024 | ||
| Joshua Reed | Director | $121K | Jun 27, 2024 |
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|